2 completed, 2 recruiting, 1 active not recruiting, 1 not yet recruiting. 7 Phase 1, 5 Phase 2, 2 Phase 3.
Follow Actinium Pharmaceuticals: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML 131I-apamistamab, Fludarabine, Cyclophosphamide - Acute Leukemia, Myeloid Leukemia | Phase 2 / Phase 3 | Not yet recruiting | Actinium Pharmaceuticals | 306 | 2026-01-01 | 2025-09-10 |
| 131I-apamistamab-based Conditioning for Hematopoietic Stem Cell Transplant (HSCT) in Advanced Sickle Cell Disease (SCD) 131I-apamistmab, Sirolimus, Campath - Sickling Disorder Due to Hemoglobin S | Phase 1 | Recruiting | Columbia University | 24 | 2025-04-28 | 2026-06-10 |
| IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCL Iomab-B, CAR-T cell - Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma | Phase 1 / Phase 2 | Recruiting | University of Texas Southwestern Medical Center | 30 | 2025-04-25 | 2026-05-08 |
| Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients Lintuzumab-Ac225, Venetoclax, Azacitidine - Acute Myeloid Leukemia, Relapsed Adult AML | Phase 1 / Phase 2 | Withdrawn | Actinium Pharmaceuticals | 2023-03-01 | 2023-07-20 | |
| Venetoclax and Lintuzumab-Ac225 in AML Patients Lintuzumab-Ac225, Venetoclax, Spironolactone - Acute Myeloid Leukemia, Relapsed Adult AML | Phase 1 / Phase 2 | Unknown | Actinium Pharmaceuticals | 38 | 2020-01-15 | 2023-08-04 |
| A Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple Myeloma Lintuzumab AC 225 - Refractory Multiple Myeloma | Phase 1 | Terminated | Actinium Pharmaceuticals | 2 | 2016-12-01 | 2022-03-08 |
| Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia Iomab-B, Conventional Care, HCT - Acute Myeloid Leukemia, Leukemia, Acute Myeloid | Phase 3 | Active not recruiting | Actinium Pharmaceuticals | 153 | 2016-06-01 | 2023-07-19 |
| Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients Cytarabine (Phase 1 only), Lintuzumab-Ac225, Furosemide (Phase 1 only) - AML | Phase 1 / Phase 2 | Completed | Actinium Pharmaceuticals | 40 | 2012-10-01 | 2023-07-20 |
| Targeted Atomic Nano-Generators (Actinium-225-Labeled Humanized Anti-CD33 Monoclonal Antibody HuM195) in Patients With Advanced Myeloid Malignancies ACTINIUM-225-LABELED HUMANIZED ANTI-CD33 MONOCLONAL ANTIBODY HuM195 - Leukemia, Myelodysplastic Syndrome | Phase 1 | Completed | Memorial Sloan Kettering Cancer Center | 23 | 2005-07-01 | 2015-02-26 |
Leukemia, Myeloid, Acute (4) · Leukemia (2) · Anemia (1) · Anemia, Sickle Cell (1) · Disease (1) · Leukemia, Myeloid (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Non-Hodgkin (1) · Multiple Myeloma (1) · Myelodysplastic Syndromes (1) · Sickle Cell Trait (1)
Spironolactone (2) · Whole-Body Irradiation (2) · venetoclax (2) · Alemtuzumab (1) · Azacitidine (1) · Cyclophosphamide (1) · Cytarabine (1) · Exchange Transfusion, Whole Blood (1) · Furosemide (1) · Immunotherapy, Adoptive (1) · Iodine (1) · Sirolimus (1) · fludarabine (1)
United States (7) · Canada (1) · Puerto Rico (1)
Avinash Desai, MD (5) · Dan Douer, MD (1) · Farrukh Awan, MD, MS, MBA (1) · Markus Y Mapara, MD (1)